Key Highlights
- Tozorakimab achieved its primary endpoint in AstraZeneca’s Phase III MIRANDA study for COPD treatment
- The investigational drug demonstrated reduced moderate-to-severe exacerbation rates compared to placebo in former and active smokers
- Trial participants received 300mg of tozorakimab bi-weekly alongside their standard treatment regimen
- These findings build on successful outcomes from the OBERON and TITANIA Phase III studies announced in March
- Regulatory submissions are planned, with full data presentation scheduled for an upcoming medical conference
AstraZeneca’s investigational chronic obstructive pulmonary disease treatment tozorakimab has successfully achieved another Phase III milestone, strengthening the drug’s clinical evidence portfolio.
Results from the MIRANDA study demonstrated that tozorakimab achieved a statistically meaningful decrease in the annual rate of moderate-to-severe COPD exacerbations when compared against placebo. These benefits were observed consistently across both the primary cohort of former smokers and the expanded population including active smokers.
Study participants were administered either tozorakimab 300mg or placebo bi-weekly in addition to their current standard therapeutic regimen. The trial specifically targeted patients who continued experiencing exacerbations while already receiving conventional inhaled medications.
Safety data aligned with previous clinical studies, with tozorakimab demonstrating a generally favorable tolerability profile.
Building on Earlier Phase III Achievements
The MIRANDA success represents the third positive Phase III outcome for tozorakimab. Earlier in March, AstraZeneca reported favorable results from the OBERON and TITANIA Phase III studies, which evaluated the medication using a monthly administration schedule.
The bi-weekly dosing regimen employed in MIRANDA provides AstraZeneca with comprehensive efficacy data across varying administration frequencies.
Tozorakimab represents a potentially groundbreaking monoclonal antibody designed to inhibit interleukin-33, an inflammatory mediator. This distinctive mechanism differentiates it from conventional inhaled COPD therapies currently available.
According to Frank Sciurba, a professor at the University of Pittsburgh serving as chief investigator for the LUNA program, these outcomes “add to the growing body of evidence that indicates tozorakimab delivered meaningful clinical benefits for COPD patients who urgently need new treatment options.”
Chronic obstructive pulmonary disease impacts approximately 400 million individuals worldwide and ranks as the third most common cause of mortality globally. More than half of affected patients experience persistent exacerbations despite adherence to standard inhaled treatment protocols — representing a significant unmet medical need that tozorakimab aims to address.
Regulatory Path Forward
AstraZeneca intends to submit MIRANDA trial data to global regulatory agencies. The pharmaceutical company also plans to share detailed findings at a forthcoming medical conference, though specific timing and venue details remain undisclosed.
Beyond COPD applications, tozorakimab is currently under investigation in Phase III clinical trials for severe viral lower respiratory tract infections and Phase II studies exploring its potential in asthma management.
The MIRANDA trial enrolled patients representing the full spectrum of blood eosinophil levels and lung function impairment stages, potentially expanding the eligible patient population for future treatment.
AstraZeneca has not yet disclosed a definitive timeline for regulatory filing submissions.
